SUMMARYBackground: Prognosis in cirrhotic patients has had a resurgence of interest because of liver transplantation and new therapies for complications of end-stage cirrhosis. The model for end-stage liver disease score is now used for allocation in liver transplantation waiting lists, replacing Child-Turcotte-Pugh score. However, there is debate as whether it is better in other settings of cirrhosis. Aim: To review studies comparing the accuracy of model for end-stage liver disease score vs. ChildTurcotte-Pugh score in non-transplant settings. Results: Transjugular intrahepatic portosystemic shunt studies (with 1360 cirrhotics) only one of five, showed model for end-stage liver disease to be superior to ChildTurcotte-Pugh to predict 3-month mortality, but not for

SUMMARY Background and AimThe potential prognostic value for survival of nutritional status in cirrhotics after adjusting Child-Pugh classification and Model for EndStage Liver Disease has not been evaluated.

No abstract

No abstract

SUMMARY BackgroundClinical trials have shown that the combination of pegylated interferon ⁄ ribavirin induces a sustained virological response in 54-63% of patients with chronic hepatitis C virus infection, but its effectiveness in day-to-day clinical practice is less clear.